Zoetis stock gains USDA license for 75-day itch treatment

Published on 11/15/2026 at 13:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zoetis stock gets a USDA license for Cytopoint Plus, a canine allergic-dermatitis treatment designed to last 75 days. The approval expands its dermatology portfolio.

Longer-acting canine dermatology therapy

Zoetis said the USDA license covers Cytopoint Plus for allergic dermatitis in dogs.
The single injection is designed to provide 75 days of allergic itch relief.
The treatment expands Zoetis' canine dermatology portfolio alongside Cytopoint and Apoquel.

ZTS, US98978V1035, Illustration mit AI erstellt.

Zoetis said on November 11, 2026, that the United States Department of Agriculture had licensed Cytopoint Plus for treating allergic dermatitis in dogs. The press release, carried by the National Law Review, describes the product as a next-generation monoclonal antibody.

USDA license extends treatment interval

Cytopoint Plus is administered as a single injection by a veterinary professional and is designed to provide 75 days of allergic itch relief. Zoetis said that interval is longer than those of existing licensed monoclonal-antibody options for canine allergic dermatitis.

The product targets interleukin-31, a protein involved in transmitting itch signals. The license expands Zoetis' canine dermatology portfolio, which also includes Cytopoint, Apoquel and Apoquel Chewable.

Portfolio relevance for Zoetis

The approval gives Zoetis another treatment option in a part of animal health that the company identifies as strategically important. A longer dosing interval may reduce scheduled injection visits for some dogs, while veterinarians retain discretion over the appropriate treatment plan.

Zoetis trades within the US equity market, represented by the S&P 500.

More news and analyses on Zoetis stock